![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Anesthesiology (C.S.K., K.M.) and Physiology and Biophysics (K.M.), University of Washington, Seattle, Washington; and Department of Pharmacology, University of Auckland, Auckland, New Zealand (K.B.-P., E.D., M.G.)
Abstract
Dopamine and endogenous cannabinoids display complex interactions in the basal ganglia. One possible level of interaction is between CB1 cannabinoid and D2 dopamine receptors. Here, we demonstrate that a regulated association of CB1 and D2 receptors profoundly alters CB1 signaling. This provides the first evidence that CB1/D2 receptor complexes exist, are dynamic, and are agonist-regulated with highest complex levels detected when both receptors are stimulated with subsaturating concentrations of agonist. The consequence of this interaction is a differential preference for signaling through a "nonpreferred" G protein. In this case, D2 receptor activation, simultaneously with CB1 receptor stimulation, results in the receptor complex coupling to G
s protein in preference to the expected Gi/o proteins. The result of this interaction is an increase in the second messenger cAMP, reversing an initial synergistic inhibition of adenylyl cyclase activity seen at subthreshold concentrations of cannabinoid agonist. Additionally, a pertussis toxin insensitive component in the activation of extracellular signal-regulated kinase (ERK) 1/2 kinases by the cannabinoid agonist CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol] is revealed in cells stably expressing both CB1 and D2 receptors. Thus, concurrent receptor stimulation promotes a heterooligomeric receptor complex and an apparent shift of CB1 signaling from a pertussis toxin-sensitive inhibition to a partly pertussis toxin-insensitive stimulation of adenylyl cyclase and ERK 1/2 phosphorylation.
Received for publication September 2, 2004.
Accepted for publication February 14, 2005.
Address correspondence to: Dr. Michelle Glass, Department of Pharmacology, University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail: m.glass{at}auckland.ac.nz
This article has been cited by other articles:
|
|
 |
|
  H. Butler and M. Korbonits Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists Eur. J. Endocrinol., November 1, 2009; 161(5): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Gaskill, T. M. Calderon, A. J. Luers, E. A. Eugenin, J. A. Javitch, and J. W. Berman Human Immunodeficiency Virus (HIV) Infection of Human Macrophages Is Increased by Dopamine: A Bridge between HIV-Associated Neurologic Disorders and Drug Abuse Am. J. Pathol., September 1, 2009; 175(3): 1148 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Ramirez, M. A. Castro, C. Angulo, L. Ramio, M. M. Rivera, M. Torres, T. Rigau, J. E. Rodriguez-Gil, and I. I. Concha The Presence and Function of Dopamine Type 2 Receptors in Boar Sperm: A Possible Role for Dopamine in Viability, Capacitation, and Modulation of Sperm Motility Biol Reprod, April 1, 2009; 80(4): 753 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gonzalez, F. Paz, L. Floran, J. Aceves, D. Erlij, and B. Floran Cannabinoid Agonists Stimulate [3H]GABA Release in the Globus Pallidus of the Rat When Gi Protein-Receptor Coupling Is Restricted: Role of Dopamine D2 Receptors J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 822 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe Endocannabinoid-Mediated Control of Synaptic Transmission Physiol Rev, January 1, 2009; 89(1): 309 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Canals and G. Milligan Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors J. Biol. Chem., April 25, 2008; 283(17): 11424 - 11434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-G. Corbille, E. Valjent, G. Marsicano, C. Ledent, B. Lutz, D. Herve, and J.-A. Girault Role of Cannabinoid Type 1 Receptors in Locomotor Activity and Striatal Signaling in Response to Psychostimulants J. Neurosci., June 27, 2007; 27(26): 6937 - 6947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ellis, J. D. Pediani, M. Canals, S. Milasta, and G. Milligan Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function J. Biol. Chem., December 15, 2006; 281(50): 38812 - 38824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance Endocr. Rev., February 1, 2006; 27(1): 73 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andersson, A. Usiello, A. Borgkvist, L. Pozzi, C. Dominguez, A. A. Fienberg, P. Svenningsson, B. B. Fredholm, E. Borrelli, P. Greengard, et al. Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons J. Neurosci., September 14, 2005; 25(37): 8432 - 8438. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
